Teva's (TEVA +0.4%) Copaxone multiple sclerosis drug performed well vs. a placebo in a Phase III trial that assessed its effectiveness under a new dosage regime of 40mg three times a week rather than the usual 20mg a day schedule
Market Data 
Markets 
AI
